+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Prostate Health Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • October 2023
  • Region: Global
  • Expert Market Research
  • ID: 5910844
The global prostate health market size was valued at USD 38.1 billion in 2023, driven by the increasing awareness and advancements in healthcare technologies across the globe. The market size is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032 to achieve a value of USD 83.4 billion by 2032.

Prostate Health: Introduction

The prostate is a small, walnut-sized gland located in the male reproductive system, situated below the bladder and in front of the rectum. It plays a crucial role in male fertility by secreting a fluid that nourishes and protects sperm, which is then mixed with sperm and other seminal fluids during ejaculation. Maintaining prostate health is essential as it impacts both the urinary and reproductive systems.

Key Trends in the Global Prostate Health Market

The global prostate health market is evolving rapidly, reflecting the increasing awareness and advancements in healthcare technologies. One dominant trend is the rising adoption of minimally invasive procedures for treating conditions like BPH. Techniques such as laser therapy and robotic-assisted surgery are gaining traction, offering shorter recovery times and reduced hospital stays. Additionally, there's a significant surge in the utilization of advanced diagnostics, with multiparametric MRI (mpMRI) emerging as a pivotal tool for more accurate prostate cancer detection, reducing unnecessary biopsies.

Concurrently, the personalization of prostate cancer treatments based on genetic profiling is driving better patient outcomes, aligning with the broader trend of precision medicine. The market is also witnessing a shift towards preventative measures; dietary supplements like saw palmetto and lycopene, believed to support prostate health, are seeing increased consumption.

Moreover, the integration of digital tools and telemedicine is revolutionizing patient monitoring and post-treatment care, particularly significant in the wake of the COVID-19 pandemic. On a global scale, awareness campaigns and prostate health initiatives are bridging the knowledge gap, leading to earlier detections and better management of prostate-related conditions. In summary, the prostate health market is in a transformative phase, shaped by technological innovations, heightened awareness, and a patient-centric approach.

Global Prostate Health Market Segmentation

Market Breakup by Treatment Type

  • Hormonal Therapy
  • Chemotherapy
  • Surgical Treatments
  • Radical Prostatectomy
  • Orchidectomy
  • Trans Urethral Resection
  • Others
  • Other Treatment Type

Market Breakup by Indications

  • Benign Prostatic Hyperplasia (BPH)
  • Prostatitis
  • Prostate Cancer
  • Others

Market Breakup by Age Group

  • Adults
  • Geriatrics
  • Others

Market Breakup by End User

  • Hospitals and Clinics
  • Speciality Clinics
  • Homecare Settings
  • Others
Market by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Prostate Health Market Overview

The global prostate health market is witnessing substantial growth, underpinned by the rising prevalence of prostate-related disorders among the aging male population. With prostate cancer being one of the most diagnosed cancers among men, the demand for early diagnostic tools, such as the PSA test and multiparametric MRI, is on the ascent. Additionally, the market is benefiting from the surge in innovative treatments and procedures, particularly minimally invasive surgeries and precision therapies tailored to individual genetic profiles.

On the therapeutic front, the adoption of advanced treatments like laser therapies, robotic-assisted surgeries, and targeted drug therapies is reshaping the care paradigm. Dietary supplements targeting prostate well-being, such as saw palmetto and lycopene, are further adding layers of growth, echoing the global shift towards preventive healthcare.

While North America remains a prominent player due to its advanced healthcare infrastructure and heightened awareness, emerging economies are experiencing accelerated growth driven by increased healthcare investments and evolving patient awareness. Challenges like overdiagnosis, potential treatment side effects, and access disparities do persist. Yet, the overall trajectory of the global prostate health market remains upward, buoyed by technological advancements, increased awareness campaigns, and a focus on early detection and prevention.

Global Prostate Health Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Abbott
  • Novartis AG
  • Teleflex
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi
  • Pfizer
  • Clovis Oncology
  • Siemens Healthcare GmbH
  • Elekta
The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Prostate Health Market Overview
3.1 Global Prostate Health Market Historical Value (2017-2023)
3.2 Global Prostate Health Market Forecast Value (2024-2032)
4 Global Prostate Health Market Landscape
4.1 Global Prostate Health Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Prostate Health Product Landscape
4.2.1 Analysis by Treatment
4.2.2 Analysis by Indications
4.2.3 Analysis by Age Group
5 Global Prostate Health Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Prostate Health Market Segmentation
6.1 Global Prostate Health Market by Treatment Type
6.1.1 Market Overview
6.1.2 Hormonal Therapy
6.1.3 Chemotherapy
6.1.4 Surgical Treatments Radical Prostatectomy Orchidectomy Trans Urethral Resection Others
6.1.5 Other Treatment Types
6.2 Global Prostate Health Market by Indications
6.2.1 Market Overview
6.2.2 Benign Prostatic Hyperplasia (BPH)
6.2.3 Prostatitis
6.2.4 Prostate Cancer
6.2.5 Others
6.3 Global Prostate Health Market by Age Group
6.3.1 Market Overview
6.3.2 Adults
6.3.3 Geriatrics
6.3.4 Others
6.4 Global Prostate Health Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Speciality Clinics
6.4.4 Homecare Settings
6.4.5 Others
6.5 Global Prostate Health Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Prostate Health Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Prostate Health Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Prostate Health Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Prostate Health Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Prostate Health Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Abbott
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Novartis AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Teleflex
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 AstraZeneca PLC
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Bayer AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Sanofi
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Pfizer
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Clovis Oncology
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Siemens Healthcare GmbH
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Elekta
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
18 Global Prostate Health Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Abbott
  • Novartis AG
  • Teleflex
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi
  • Pfizer
  • Clovis Oncology
  • Siemens Healthcare GmbH
  • Elekta